Introduction: Clinical pharmacogenomic guidelines are available, but implementation in Brazil's Unified Health System (SUS) faces testing costs, fragmented care pathways and limited reuse of results. Objective: To examine the determinants of pharmacogenomic costs and value in the SUS and to propose FARMA-GEN SUS, an author-proposed implementation model not adopted by the Ministry of Health, combining a multigene panel triggered by a first high-yield clinical indication, interoperable records and pharmacist–prescriber collaboration. Methods: Critical, proposal-oriented essay integrating clinical trials, economic evaluations, Brazilian population studies and regulatory documents in force on 13 October 2026, supplemented by targeted PubMed and BVS/LILACS searches. Published evidence, illustrative calculations and implementation proposals were considered separately; no primary clinical data were collected. Synthesis: In PREPARE, clinically relevant adverse drug reactions among patients with actionable gene–drug interactions occurred in 21.0% of the guided group versus 27.7% of controls (OR 0.70; 95% CI 0.54–0.91). The associated economic analysis identified the test price as a major cost driver, without establishing savings for Brazil. The proposed model prioritises high-yield clinical triggers, fit-for-purpose analytical coverage, structured recording, clinical interpretation and later reuse. An illustrative CYP2C19–clopidogrel break-even exercise used hypothetical clinical assumptions and a non-significant effect from TAILOR-PCI; with median public-purchase prices (2025–2026), the annual incremental cost of ticagrelor far exceeded the break-even ceilings against clopidogrel, whereas a counterfactual against universal ticagrelor suggested possible savings. Results depend on effect size, medicine and test costs and the comparator; the exercise is not a cost-effectiveness study. Conclusion: Savings for the SUS have not been demonstrated. FARMA-GEN SUS should be evaluated in a prospective comparative pilot measuring health outcomes (events avoided, QALYs), safety, micro-costed expenditure, access, implementation and budget impact before any scale-up.